title: [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
abstract: OBJECTIVE
  The expression of CD95(Fas/APO-1) antigen was studied on bone marrow cells of 19 MDS patients, peripheral blood blast cells of 15 acute myeloid leukemia (AML) patients, blast cells and granulocytes of 68 patients with chronic myeloid leukemia (CML)--24 in chronic, 9 in accelerated phase and 35 in blastic crisis (BC)--by indirect surface immunofluorescence assay using flow cytometry (FACScan, Becton Dickinson, USA).
  
  
  RESULTS
  CD95(Fas/APO-1) antigen was revealed on bone marrow cells of 8 out of 19 (36.8%) MDS patients; the percentage of antigen-positive cells was 38.1 +/- 19.2%; on 45.5 +/- 22.8% of cells in 6(45%) of 15 AML patients. Fas/APO-1 antigen was totally absent in CML chronic stage; its expression was found in 34% (12 of 35) of our patients with CML BC on peripheral blood blasts and in 56% (5 of 9) on peripheral blast cells of CML patients in acceleration phase.
  
  
  CONCLUSIONS
  The data on overall survival of CD95-positive MDS patients suggest that the presence of Fas antigen is a favorable prognostic sign for patients with MDS. The patients from CD95-negative group represent a risk group both for survival and AML transformation. In CML BC group the survival does not depend upon Fas-antigen expression.
authors.forename: E R
authors.initials: ER
authors.lastname: Polosukhina
authors.forename: S V
authors.initials: SV
authors.lastname: Kuznetsov
authors.forename: N P
authors.initials: NP
authors.lastname: Logcheva
authors.forename: T N
authors.initials: TN
authors.lastname: Zabotina
authors.forename: M R
authors.initials: MR
authors.lastname: Tenuta
authors.forename: A D
authors.initials: AD
authors.lastname: Shirin
authors.forename: G I
authors.initials: GI
authors.lastname: Kaletin
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
authors.forename: N V
authors.initials: NV
authors.lastname: Tsvetaeva
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Shishkin
authors.forename: Z G
authors.initials: ZG
authors.lastname: Kadagidze
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
authors.forename: M A
authors.initials: MA
authors.lastname: Volkova
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Baryshnikov
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal; D001752:Blast Crisis / Q000276:immunology / Q000401:mortality; D001773:Blood Cells / Q000276:immunology*; D001854:Bone Marrow Cells / Q000276:immunology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D019014:fas Receptor / Q000032:analysis*
chemical_list: D000911:Antibodies, Monoclonal; D019014:fas Receptor